Clinical Trials Logo

Neoplasms, Plasma Cell clinical trials

View clinical trials related to Neoplasms, Plasma Cell.

Filter by:

NCT ID: NCT00048230 Completed - Multiple Myeloma Clinical Trials

PS-341 (VELCADEā„¢) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Start date: June 2002
Phase: Phase 3
Study type: Interventional

This study will compare the efficacy of PS-341 versus high dose dexamethasone.

NCT ID: NCT00047788 Completed - Multiple Myeloma Clinical Trials

Efficacy Study of ZD6474 to Treat Multiple Myeloma Cancer

Start date: October 2002
Phase: Phase 2
Study type: Interventional

The primary objective is to assess the efficacy of ZD6474 when given orally to patients with relapsed multiple myeloma. A minimum of 15 and a maximum of 30 evaluable patients will be entered on study

NCT ID: NCT00047203 Completed - Clinical trials for Refractory Multiple Myeloma

Flavopiridol in Treating Patients With Relapsed or Refractory Multiple Myeloma

Start date: September 2002
Phase: Phase 2
Study type: Interventional

Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Phase II trial to study the effectiveness of flavopiridol in treating patients who have relapsed or refractory multiple myeloma

NCT ID: NCT00046852 Completed - Infection Clinical Trials

Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma

Start date: December 2001
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with autologous peripheral stem cell transplantation and immunotherapy may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. PURPOSE: Randomized phase I/II trial to study the effectiveness of combining chemotherapy with peripheral stem cell transplantation followed by immunotherapy in treating patients who have multiple myeloma.

NCT ID: NCT00045136 Completed - Clinical trials for Multiple Myeloma and Plasma Cell Neoplasm

Chemotherapy, Holmium Ho 166 DOTMP, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Start date: January 2002
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Holmium Ho 166 DOTMP may deliver radiation directly to cancer cells and cause less damage to normal tissue. Combining chemotherapy and holmium Ho 166 DOTMP with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy and holmium Ho 166 DOTMP and kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combining holmium Ho 166 DOTMP with melphalan and peripheral stem cell transplantation in treating patients who have multiple myeloma.

NCT ID: NCT00044954 Completed - Lymphoma Clinical Trials

Total-Body Irradiation, Fludarabine, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Start date: November 1999
Phase: Phase 2
Study type: Interventional

RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with donor peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining total-body irradiation with fludarabine and donor peripheral stem cell transplantation in treating patients who have hematologic cancer.

NCT ID: NCT00044018 Completed - Multiple Myeloma Clinical Trials

CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma

Start date: April 1, 2002
Phase: Phase 2
Study type: Interventional

The purpose of the study is to select the dose regimen of CDC-501 that provides the most promising evidence of efficacy.

NCT ID: NCT00042900 Completed - Lymphoma Clinical Trials

Pyroxamide in Treating Patients With Advanced Cancer

Start date: April 2002
Phase: Phase 1
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of pyroxamide in treating patients who have advanced cancer.

NCT ID: NCT00038233 Completed - Multiple Myeloma Clinical Trials

Thalidomide for Multiple Myeloma

Start date: May 1999
Phase: Phase 3
Study type: Interventional

The objective of this protocol is to assess therapeutic activity of thalidomide in previously untreated patients with asymptomatic multiple myeloma.

NCT ID: NCT00038090 Completed - Multiple Myeloma Clinical Trials

Thalidomide-Dexamethasone for Multiple Myeloma

Start date: June 2000
Phase: Phase 2/Phase 3
Study type: Interventional

Objective is to assess the activity of the combination of thalidomide and dexamethasone in patients with previously untreated multiple myeloma.